Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirotinib in advanced solid tumors
NCT02442414Phase 1Completed
- Sponsor
- Sihuan Pharmaceutical
- Start
- Apr 2015
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pirotinib in solid tumor (advanced stage), sponsored by Sihuan Pharmaceutical. Primary endpoint: Safety and tolerability based on DLTs, toxicity grade, and reversibility at 2 Years. Started Apr 2015; status: completed.
02
Drugs
pirotinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02442414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442414.